Regulatory changes to the nursing home industry for this year may seem small individually, but together, they reflect broader initiatives sought by the ...

CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...

The two companies have inked a deal allowing Yatiri to identify biomarkers that could improve FHD-286's efficacy in advanced AML and MDS patients.

A major study led by the University of Hertfordshire has shown how linking care home data with NHS and social care records can improve residents' lives, strengthen policy decision-making and ensure ...

Georgia School of Orthodontics (GSO) announced the appointment of Mohamed I. Masoud, BDS, DMSc, a Diplomate of the American Board of Orthodontics, as its new Director of Research. A distinguished ...

Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International ...

Building closer relationships with facility staff and health care partners of nursings homes, such as hospital providers and pharmacies, is going to be ...

Rytelo (imetelstat) is a medicine used to treat myelodysplastic syndromes (MDS). MDS is a rare group of disorders that affect your blood cells. Most people who get MDS are 65 years of age or older, ...